Author

M. I. Harrell

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Assay:DNA methylation· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

E. M. Swisher· 2 shared A. Ashworth· 1 shared A. DeFazio· 1 shared A. Dobrovic· 1 shared A. Drean· 1 shared A. Musafer· 1 shared A. Swain· 1 shared C. J. Lord· 1 shared

Activity by Year

2017-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

E. M. Swisher

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Acquired RAD51C promoter methylation loss causes PARP inhibitor resistance in high grade serous ovarian carcinoma

K. Nesic, O. Kondrashova, R. M. Hurley, C. McGehee, C. J. Vandenberg, G.-Y. Ho, E. Lieschke, G. Dall, N. Bound, K. Shield-Artin, M. R. Radke, A. Musafer, Z. Qing Chai, M. R. Eftekhariyan Ghamsari, M. I. Harrell, , C. L. Scott

This study shows that loss of RAD51C promoter methylation leads to PARP inhibitor resistance in high-grade serous ovarian carcinoma, independent of BRCA1 methylation status.

bioRxiv · Dec 10, 2020Cancer Biology

Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance

S. J. Pettitt, D. B. Krastev, I. Brandsma, A. Drean, F. Song, R. Aleksandrov, M. I. Harrell, M. Menon, R. Brough, J. Campbell, J. Frankum, M. Ranes, H. N. Pemberton, R. Rafiq, K. Fenwick, , C. J. Lord

The paper identifies PARP1 point mutations causing PARP inhibitor resistance through CRISPR-Cas9 screens and shows their impact on PARP1 trapping and chemotherapy sensitivity.

bioRxiv · Oct 14, 2017Cancer Biology